Escherichia coli resistance to quinolones at a comprehensive cancer center.
As part of Meropenem Yearly Susceptibility Test Information Collection/USA Surveillance Programme, we monitored the occurrence of quinolone resistance in Escherichia coli over a 10-year period. A total of 271 E. coli isolates from our institution were tested over a 10-year period. Screening for quinolone resistance (qnr) gene was performed. A decline in susceptibility of E. coli isolates to quinolones and aminoglycosides was noted over the 10-year span (P < 0.0001), which was significantly reduced compared with the average susceptibility of all sites. Introduction of quinolone prophylaxis has led to a significant decline in susceptibility of E. coli to all quinolones. The organisms remain susceptible to carbapenems, cefepime, and piperacillin/tazobactam. Periodic surveillance allows for detection of resistance patterns and adjustment of empiric antibiotic choice in patients at high risk for infection.
Mihu
Coralia N
CN
Department of Infectious Diseases, Infection Control and Employee Health, The UT M.D. Anderson Cancer Center, Houston, TX 77030, USA. cnmihu@mdanderson.org
Rhomberg
Paul R
PR
Jones
Ronald N
RN
Coyle
Elizabeth
E
Prince
Randall A
RA
Rolston
Kenneth V
KV
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D002173:Cancer Care Facilities; D024881:Drug Resistance, Bacterial; D004926:Escherichia coli / Q000187:drug effects* / Q000302:isolation & purification; D004927:Escherichia coli Infections / Q000382:microbiology*; D006801:Humans; D008826:Microbial Sensitivity Tests; D015363:Quinolones / Q000494:pharmacology*; D014481:United States
D000900:Anti-Bacterial Agents; D015363:Quinolones